Core Viewpoint - A securities class action lawsuit has been filed against Kyverna Therapeutics, Inc. for allegedly making materially false and misleading statements in connection with its February 8, 2024 IPO [1][2]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased Kyverna common stock during its IPO [1]. - The lead plaintiff deadline for the lawsuit is set for February 7, 2025 [1][3]. - The complaint alleges that Kyverna failed to disclose adverse data related to one of its clinical trials at the time of the IPO [2]. Group 2: Lead Plaintiff Process - Investors may seek to be appointed as a lead plaintiff representative of the class by the deadline or may choose to remain absent [3]. - The lead plaintiff is typically the investor or small group of investors with the largest financial interest in the case [3]. Group 3: Law Firm Background - Kessler Topaz Meltzer & Check, LLP has a reputation for prosecuting class actions and has recovered billions for victims of corporate misconduct [4].
KYTX Class Action Alert: Kessler Topaz Meltzer & Check, LLP Reminds Kyverna Therapeutics, Inc. (KYTX) Shareholders of Securities Fraud Class Action Lawsuit Deadline